Ioxilan
![]() | |
Clinical data | |
---|---|
Trade names | Oxilan |
AHFS/Drugs.com | FDA Professional Drug Information |
Routes of administration | intravenously |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | negligible |
Metabolism | none |
Elimination half-life | 2 hours |
Excretion | Mostly renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H24I3N3O8 |
Molar mass | 791.116 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]
Mechanism of action
[edit]Ioxilan is an iodinated contrast agent.[2]
References
[edit]- ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969.
- ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07.